A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype

被引:19
作者
Kerem, E
NissimRafinia, M
Argaman, Z
Augarten, A
Bentur, L
Klar, A
Yahav, Y
Szeinberg, A
Hiba, O
Branski, D
Corey, M
Kerem, B
机构
[1] HEBREW UNIV JERUSALEM, DEPT GENET, IL-91904 JERUSALEM, ISRAEL
[2] CHAIM SHEBA MED CTR, DEPT PAEDIAT, CF CLIN, IL-52621 TEL HASHOMER, ISRAEL
[3] RAMBAM MED CTR, DEPT PAEDIAT, CF CLIN, HAIFA, ISRAEL
[4] BIKUR CHOLIM HOSP, DEPT PAEDIAT, JERUSALEM, ISRAEL
[5] HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1X8, CANADA
关键词
cystic fibrosis; genotype-phenotype correlation; genetics; pancreatic function; pulmonary function; CFTR mutation;
D O I
10.1542/peds.100.3.e5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. Cystic fibrosis (CF) has variable clinical presentation. Disease severity is partially associated with the type of mutation. The aim of this study was to report genotype-phenotype analysis of the G85E mutation. Patients. The phenotype of 12 patients (8 were from the same extended family, and 5 of them were siblings from 2 families) carrying at least one copy of the G85E mutation was evaluated and compared with the phenotype of 40 patients carrying the two severe mutations, W1282X and/or Delta F508 (group 1), and with 20 patients carrying the splicing mutation, 3849+10kb C->T, which was found to be associated with milder disease (group 2). Results. A high phenotypic variability was found among the patients carrying the G85E mutation. This high variability was found among patients carrying the same genotype and among siblings. All the studied chromosomes carrying the G85E mutation had the 7T variant in the polythymidine tract at the branch/acceptor site in intron 8. Of the G85E patients, 25% had pancreatic sufficiency and none had meconium ileus, compared with 0% and 32%, respectively, of patients from group 1, and 80% and 0%, respectively, from group 2. Two patients carrying the G85E mutation had sweat chloride levels <60 mmol/L whereas all the others had typically elevated levels >80 mmol/L. Compared with group 2, patients carrying the G85E mutation were diagnosed at an earlier age and had higher sweat chloride levels, with mean values similar to group 1 but significantly more variable. Forced expiratory volume in 1 second (FEV1) was similar in the three groups, with no differences in the slope or in age-adjusted mean values of FEY. The levels of transcripts lacking exon 9 transcribed from the G85E allele measured in 3 patients were 55%, 49%, and 35% and their FEV1 values were 82%, 83%, and 50% predicated, respectively. Conclusions. The G85E mutation shows variable clinical presentation in all clinical parameters. This variability could be seen among patients carrying on the other chromosome the same CFTR mutation, and also among siblings. This variability is not associated with the level of exon 9 skipping. Thus, the G85E mutation cannot be classified either as a severe or as a mild mutation.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies
    Anwar, Saba
    Peng, Jin-Liang
    Zahid, Kashif Rafiq
    Zhou, Yu-Ming
    Ali, Qurban
    Qiu, Chong-Rong
    ADVANCES IN RESPIRATORY MEDICINE, 2024, 92 (04) : 263 - 277
  • [42] Targeted Therapy for Cystic FibrosisCystic Fibrosis Transmembrane Conductance Regulator Mutation-Specific Pharmacologic Strategies
    Ronald C. Rubenstein
    Molecular Diagnosis & Therapy, 2006, 10 : 293 - 301
  • [43] EXCESS FLUORIDE INTERFERENCE WITH CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)
    Clinch, Carole
    FLUORIDE, 2011, 44 (01) : 7 - 8
  • [44] Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers
    Cantin, Andre M.
    Hanrahan, John W.
    Bilodeau, Ginette
    Ellis, Lynda
    Dupuis, Annie
    Liao, Jie
    Zielenski, Julian
    Durie, Peter
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (10) : 1139 - 1144
  • [45] Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking
    Carlile, Graeme W.
    Robert, Renaud
    Goepp, Julie
    Matthes, Elizabeth
    Liao, Jie
    Kus, Bart
    Macknight, Sean D.
    Rotin, Daniela
    Hanrahan, John W.
    Thomas, David Y.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (01) : 16 - 25
  • [46] Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis
    Ooi, Chee Y.
    Durie, Peter R.
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (05) : 355 - 362
  • [47] A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators
    Gavioli, Elizabeth Marie
    Guardado, Nerli
    Haniff, Farah
    Deiab, Nouran
    Vider, Etty
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (02) : 286 - 294
  • [48] Ionocyte-Specific Regulation of Cystic Fibrosis Transmembrane Conductance Regulator
    Sato, Yukiko
    Kim, Dusik
    Turner, Mark J.
    Luo, Yishan
    Zaidi, Syeda Sadaf Zehra
    Thomas, David Y.
    Hanrahan, John W.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2023, 69 (03) : 281 - 294
  • [49] Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction
    Toprak, Demet
    Davis, Chelsea
    Rosenfeld, Margaret
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 40 (06) : 751 - 761
  • [50] Identification of cystic fibrosis transmembrane conductance regulator gene (CFTR) variants
    Almaghamsi, Talal
    Attiyah, Wejdan Ba
    Bahasan, Mona
    Alotaibi, Badi A.
    Alahmadi, Shahad F.
    Hanbazazh, Mehenaz
    Zakariyah, Abeer
    Saleem, Rimah A.
    AlAnezi, Munaifah K.
    Hawsawi, Yousef
    SAUDI MEDICAL JOURNAL, 2023, 44 (10) : 987 - 994